Covid-19: WHO panel set to decide on emergency use of Chinese vaccine

A key World Health Organisation panel was set to decide Friday whether to authorize emergency of a Chinese-made COVID-19 vaccine, a WHO spokesperson said, potentially paving the way for millions of doses to reach needy countries through a U.N.-backed program.

The review by a technical advisory group could open the possibility of the Sinopharm vaccine being included in the UN-backed COVAX programme in the coming weeks or months, and distributed through WHO's regional office for the Americas and the UN children's agency UNICEF.

WHO spokesman Christian Lindmeier said a decision was expected later Friday.

Apart from efficacy information, Sinopharm has released very little public data about its two vaccines - one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.

The Beijing shot is one that WHO is considering for an emergency use listing.

A separate group advising the UN agency on vaccines said it was very confident the Sinopharm vaccine protects people ages 18-59. The group said it had a low level of confidence of vaccine's efficacy in people 60 and over. It expressed very low confidence in the available data about potentially serious side effects in that age group.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel